Flufenamic Acid: Growth Modulating Effects on Human Aortic Smooth Muscle Cells In Vitro

• Published in: Journal of vascular and interventional radiology Vol. 13; no. 1; pp. 89 - 96
• Main Authors: Schöber, Wolfgang, Wiskirchen, Jakub, Kehlbach, Rainer, Gebert, Regina, Rodegerdts, Enno, Betsch, Angelika, Johst, Ursula, Claussen, Claus D., Duda, Stephan H.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 2002
• Subjects: Anti-Inflammatory Agents, Non-Steroidal - pharmacology; Aorta; Blood vessels, stenosis or obstruction; Blotting, Western; Cell Cycle - drug effects; Cell Movement - drug effects; Cells, Cultured; Flow Cytometry; Flufenamic acid; Flufenamic Acid - pharmacology; Humans; Kinetics; Mitogen-Activated Protein Kinases - drug effects; Muscle, Smooth, Vascular - cytology; Muscle, Smooth, Vascular - drug effects; Muscle, Smooth, Vascular - metabolism; Restenosis; Smooth muscle cells; Restenosis; haSMC = human aortic smooth muscle cell; MAPK = mitogen activated protein kinase; BLU = Boehringer light units; Flufenamic acid; PDGF = platelet derived growth factor; PTA = percutaneous transluminal angioplasty; Blood vessels, stenosis or obstruction; SMC = smooth muscle cell; Smooth muscle cells
• ISSN: 1051-0443; 1535-7732
• DOI: 10.1016/S1051-0443(07)60014-1

The aim of the study was to examine the effects of flufenamic acid on proliferation, clonogenic activity, migratory ability, cell-cycle distribution, and p44/42-mitogen-activated protein kinase (MAPK) expression on serum-stimulated human aortic smooth muscle cells (haSMCs) in vitro. HaSMCs were treated with flufenamic acid in three different doses (40 μmol/L, 200 μmol/L, 400 μmol/L) for 4 days, and then flufenamic-acid-free culture medium was supplemented every 4 days until day 20 after initial treatment. The growth kinetics were assessed. Cell-cycle analysis was performed by flow cytometry. The clonogenic activity was evaluated with use of colony formation assays. The migratory ability was investigated by stimulation with platelet derived growth factor (PDGF-BB) in 24 well plates with 8-μm pore membrane inserts. The p44/42 MAPK was detected by Western blot technique. Flufenamic acid inhibited the proliferation (400 μmol/L treatment over 4 d; 179,700 ± 49,800 vs 747,900 ± 144,000; P < .001), clonogenic activity (400 μmol/L treatment over 4 d; 1 ± 0.3 vs 50 ± 1.4; P < .001) and migratory ability (400 μmol/L treatment over 4 d; 8 cells ± 2 vs 48 cells ± 15; P < .001) of haSMCs in a dose-dependent manner. Cell-cycle analysis revealed a G2/M-phase block (400 μmol/L treatment over 4 d; 28.9 ± 1.5 vs 9.5 ± 3.2; P < .001). The expression of p44/42 MAPK was reduced for a treatment with 400 μmol/L flufenamic acid (controls, 427 BLU ± 0.305 vs treatment group, 190 BLU ± 106; P < .05) Flufenamic acid inhibits the proliferation and migration of haSMCs. Further experiments with animal models concerning stenosis and restenosis are necessary to evaluate the potential of this promising drug.